# Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

> **NCT03009396** · PHASE3 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 54 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

## Key facts

- **NCT ID:** NCT03009396
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-18
- **Primary completion:** 2018-11-13
- **Final completion:** 2019-08-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03009396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03009396, "Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03009396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*